Synthetic route eliminates need for high potency equipment during manufacture of proprietary drug candidates
Fort Collins, CO, February 25, 2025 – Cetya Therapeutics, Inc. today announced issuance of US Patent No. 12,227,522 covering its novel process for the manufacture of CT-101, Cetya’s lead proprietary HDAC inhibitor, as well as other HDAC inhibitors in its portfolio such as CT-102 and CT-108. The improved synthetic routes increase efficiency for manufacturing of key analogues and eliminate steps through high potency intermediates requiring usage of high-containment production equipment to protect production personnel.
Originally, the synthetic routes for the analogues included a step where a bioactive intermediate was produced prior to the final step where the parent compound is formed. The improved synthetic routes revised this step to now incorporate an inactive intermediate that is biologically inert and thus much safer
to handle. “We are excited with issuance of the process patent in the US and are pursuing world-wide rights to the technology to build on Cetya’s IP estate” stated Louis Junker, CSO of Cetya. “The improved synthetic routes represent an advancement in the efficient production of our novel HDAC inhibitors that can be used for treating cancer and hemoglobinopathies”. “This patent exemplifies Cetya’s position as a leader in novel HDAC inhibitor chemistry, radically altering the manufacturing process for its novel HDAC inhibitors to improve the process safety for production personnel and reduce the capital needs for scale up and manufacture of clinical grade material” stated John Adair, CEO of Cetya. “
About Cetya Therapeutics
Cetya Therapeutics, Inc. is a development stage pharmaceutical company advancing histone deacetylase (HDAC) inhibitors structurally based on the marine natural product Largazole. Cetya has exclusive and worldwide rights to synthesis and use of the HDAC inhibitor platform and patent estate developed in the laboratory of Dr. Robert M. Williams at Colorado State University. Cetya has a portfolio of analogues including CT-101, its Lead analogue with potential applications for treatment of cancer, sickle cell disease and chronic inflammatory conditions. Cetya is seeking corporate partners to assist in the advancement of its analogue portfolio in therapeutic areas where epigenetic drugs are effective. For more information on Cetya, please visit our website at www.cetyatherapeutics.com or contact John Adair at jadair@cetyatherapeutics.com .